The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / GSK Shuts U.S. Plant Due to Bacteria

GSK Shuts U.S. Plant Due to Bacteria

August 13, 2015 • By Karen Brooks & Ben Hirschler

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Drugmaker GlaxoSmithKline temporarily closed a North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire’s disease.

You Might Also Like
  • GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy
  • U.K. Cost Body Finally Approves Limited Use of GSK’s Lupus Drug
  • U.S. Bans Another Indian Drug Plant over Production Quality

The Legionella bacteria were discovered during routine inspections at the site in Zebulon, N.C., the company said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The shutdown is not expected to disrupt supplies of medicines made at the factory, which include GSK’s $7 billion-a-year inhaled respiratory drug Advair (fluticasone propionate). Advair is also made at two other sites in Ware, England, and Evreux, France.

GSK said the shutdown was a precautionary measure and the Zebulon site would reopen when the situation was remedied. The tower is a stand-alone structure that does not come in contact with any products.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The cooling towers will be cleaned and retested before the site goes back into operation. GSK is taking these precautions to ensure the health and safety of our employees, as well as the safety and integrity of our products,” the group said in a statement.

Spokeswoman Jenni Brewer Ligday said 600 workers were sent home or told not to come in while the towers were being cleaned.

City and state officials said the discovery did not warrant a public health alert and that no threat was posed to city drinking water, according to a report in the Charlotte News and Observer newspaper.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Zebulon plant manufactures around 30 different GSK drugs in all, including malaria drug Malarone (atovaquone and proguanil), HIV treatment Combivir (lamivudine and zidovudine) and Requip (ropinorole hydrochloride) for Parkinson’s disease, but its biggest product line is Advair, for asthma and chronic lung disease.

GSK is also planning to produce its next-generation dry powder inhaled respiratory drugs, such as Breo and Anoro, at Zebulon, although for the moment these are only being made in Ware.

Legionella bacteria are found naturally in warm water and thrive in environments such as hot tubs, cooling towers, water tanks, large plumbing systems and fountains, according to the U.S. Centers for Disease Control and Prevention.

Legionnaire’s disease, a severe kind of pneumonia, is contracted by breathing in mist containing the bacteria. It is not contagious, according to the CDC.

Last week, New York City’s Department of Health ordered the inspection and cleaning of all cooling towers in the city in response to an outbreak of Legionnaire’s’ disease that has claimed 12 lives.

Filed Under: Drug Updates, Pharma Co. News, Safety Tagged With: GlaxoSmithKline, Legionnaire's disease, public health

You Might Also Like:
  • GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy
  • U.K. Cost Body Finally Approves Limited Use of GSK’s Lupus Drug
  • U.S. Bans Another Indian Drug Plant over Production Quality
  • Don’t Bank on U.S. Drug Price Rises, Warns GSK Boss

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)